EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

RNA sequencing detects more challenging cases of somatic hypermutation in the IgHV gene in patients with chronic lymphocytic leukemia ​

Fatma Arikan iD, Pınar Ata iD, Şenol Demir iD, Meral Uluköylü Mengüç iD, Fahir Özkalemkaş iD, Bedrettin Orhan iD, Özgür Mehtap iD, Arda Bayar iD, Asu Fergün Yilmaz iD, Ayşe Tülin Tuğlular iD, Işık Atagündüz iD, Tayfur Toptaş iD

Turkish Journal of Medical Sciences · 13.08.2026 · 56 (4) · 1133-1140

DOI: 10.55730/1300-0144.6357 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Turkish Journal of Medical Sciences, online erschienen am 13.08.2026. Verfasst von Fatma Arikan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Marmara University Pendik Training and Research Hospital, İstanbul, Tur…. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Somatic Hypermutation, Immunoglobulin, Sequence Analysis, RNA, Immunoglobulin Heavy Chains. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/aim: Chronic lymphocytic leukemia (CLL) exhibits marked biological heterogeneity, and immunoglobulin heavy chain variable (IgHV) mutation status remains a key prognostic biomarker. We evaluated patient IgHV status via RNA sequencing (RNA-seq) and examined real-life clinical outcomes in a retrospective CLL cohort. Materials and methods: Eighty-seven adults diagnosed with CLL between 2020 and 2022 at three centers were included. Total RNA from peripheral blood underwent anchored multiplex polymerase chain reaction with the Immunoverse BCR-IGH IGKL v1.0 kit (Integrated DNA Technologies) and was sequenced on the MiSeq platform (Illumina). IgHV mutation status was determined according to ERIC 2022 guidelines, specifically regarding classification of “challenging” double-rearranged cases, with discordant productive rearrangements (one mutated, one unmutated) categorized as unmutated (u-IgHV) to ensure prognostic reliability. Clinical characteristics, treatment patterns, and survival outcomes were analyzed and overall survival (OS) was estimated by the Kaplan–Meier method.

Results

Median age at diagnosis was 60 years and 64% of patients were male. RNA-seq identified double IgHV rearrangements in 73% (n = 63) of patients, 63% of whom harbored two productive rearrangements without evidence of biclonality. Unmutated IgHV (u-IgHV) was observed in 53% (n = 46). Compared to mutated IgHV (m-IgHV), patients with u-IgHV more frequently required first-line therapy (66% vs. 34%) and proceeded to second-line treatment more rapidly. Deletion 17p was significantly more common in the u-IgHV group. After median follow-up of 37.5 months, the 3-year OS rate was 91.9%, with no significant difference in OS between the m-IgHV and u-IgHV cohorts.

Conclusion

RNA-seq provided detailed insight into IgHV mutation status and revealed a higher incidence of challenging double-rearranged cases. These real-life findings underscore the clinical utility of RNA-based IgHV profiling and support its use. Prospective studies comparing RNA- and DNA-based assays are warranted to validate concordance and inform risk-adapted management strategies in the treatment of CLL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellSomatic Hypermutation, ImmunoglobulinSequence Analysis, RNAImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionHumansMaleFemaleRetrospective StudiesMiddle AgedAgedMutationPrognosisAdult

Stichwörter der Autor:innen

Chronic lymphocytic leukemiaRNA sequencingsomatic hypermutation

Substanzen

Immunoglobulin Heavy ChainsImmunoglobulin Variable Region

Autor:innen und Institutionen

  • Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Marmara University Pendik Training and Research Hospital, İstanbul, Turkiye.
  • Division of Genetics and Molecular Research, Department of Medical Genetics, Faculty of Medicine, Marmara University Pendik Training and Research Hospital, İstanbul, Turkiye.
  • Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Uludağ University, Bursa, Turkiye.
  • Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Kocaeli University, Kocaeli, Turkiye.

ORCID-Profile: Fatma Arikan, Pınar Ata, Şenol Demir, Meral Uluköylü Mengüç, Fahir Özkalemkaş, Bedrettin Orhan, Özgür Mehtap, Arda Bayar, Asu Fergün Yilmaz, Ayşe Tülin Tuğlular, Işık Atagündüz, Tayfur Toptaş

Zitieren

APA

Arikan, F., Ata, P., Demir, Ş., Uluköylü Mengüç, M., Özkalemkaş, F., Orhan, B., Mehtap, Ö., Bayar, A., Yilmaz, A. F., Tuğlular, A. T., Atagündüz, I., & Toptaş, T. (2026). RNA sequencing detects more challenging cases of somatic hypermutation in the IgHV gene in patients with chronic lymphocytic leukemia ​. Turkish Journal of Medical Sciences, 56(4), 1133-1140. https://doi.org/10.55730/1300-0144.6357

Vancouver

Arikan F, Ata P, Demir Ş, Uluköylü Mengüç M, Özkalemkaş F, Orhan B, et al. RNA sequencing detects more challenging cases of somatic hypermutation in the IgHV gene in patients with chronic lymphocytic leukemia ​. Turkish Journal of Medical Sciences. 2026;56(4):1133-1140. doi:10.55730/1300-0144.6357

BibTeX
@article{Arikan2026,
  author = {Arikan, Fatma and Ata, Pınar and Demir, Şenol and Uluköylü Mengüç, Meral and Özkalemkaş, Fahir and Orhan, Bedrettin and Mehtap, Özgür and Bayar, Arda and Yilmaz, Asu Fergün and Tuğlular, Ayşe Tülin and Atagündüz, Işık and Toptaş, Tayfur},
  title = {RNA sequencing detects more challenging cases of somatic hypermutation in the IgHV gene in patients with chronic lymphocytic leukemia ​},
  journal = {Turkish Journal of Medical Sciences},
  year = {2026},
  volume = {56},
  number = {4},
  pages = {1133--1140},
  doi = {10.55730/1300-0144.6357}
}
Kostenlos starten →